Susquehanna International Group, LLP Legend Biotech Corp Call Options Transaction History

Susquehanna International Group, LLP

13 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$39.5 - $57.22 $9.61 Million - $13.9 Million	-243,400 Reduced 79.05%	64,500 $2.86 Million
Q1 2024 May 07, 2024	BUY	$55.06 - $69.99 $7.45 Million - $9.47 Million	135,300 Added 78.39%	307,900 $17.3 Million
Q4 2023 Feb 14, 2024	BUY	$57.25 - $69.74 $9.01 Million - $11 Million	157,300 Added 1028.1%	172,600 $10.4 Million
Q3 2023 Nov 14, 2023	SELL	$63.16 - $76.5 $3.83 Million - $4.64 Million	-60,700 Reduced 79.87%	15,300 $1.03 Million
Q2 2023 Aug 11, 2023	SELL	$46.28 - $75.01 $199,004 - $322,543	-4,300 Reduced 5.35%	76,000 $5.25 Million
Q1 2023 May 16, 2023	SELL	$43.42 - $57.37 $5.2 Million - $6.87 Million	-119,800 Reduced 59.87%	80,300 $3.87 Million
Q4 2022 Feb 14, 2023	SELL	$38.8 - $55.46 $12.3 Million - $17.5 Million	-316,200 Reduced 61.24%	200,100 $9.99 Million
Q3 2022 Nov 14, 2022	BUY	$38.15 - $57.1 $11.3 Million - $16.9 Million	296,500 Added 134.9%	516,300 $21.1 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $55.0 $2.66 Million - $4.36 Million	79,200 Added 56.33%	219,800 $12.1 Million
Q1 2022 May 16, 2022	BUY	$31.02 - $48.18 $3.93 Million - $6.1 Million	126,700 Added 911.51%	140,600 $5.11 Million
Q4 2021 Feb 14, 2022	SELL	$41.14 - $56.98 $633,556 - $877,492	-15,400 Reduced 52.56%	13,900 $648,000
Q3 2021 Nov 15, 2021	BUY	$35.31 - $50.56 $741,510 - $1.06 Million	21,000 Added 253.01%	29,300 $1.48 Million
Q2 2021 Aug 11, 2021	BUY	$25.8 - $41.09 $214,140 - $341,047	8,300 New	8,300 $341,000

198

74.2M

374K

387K

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $8.25B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.